These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23490149)

  • 1. Improving the immunostimulatory potency of diethanolamine-containing lipid A mimics.
    Lewicky JD; Ulanova M; Jiang ZH
    Bioorg Med Chem; 2013 Apr; 21(8):2199-2209. PubMed ID: 23490149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of a dimeric monosaccharide lipid A mimic and its synergistic effect on the immunostimulatory activity of lipopolysaccharide.
    Lewicky JD; Ulanova M; Jiang ZH
    Carbohydr Res; 2011 Sep; 346(13):1705-13. PubMed ID: 21689810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
    Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
    Front Immunol; 2021; 12():631797. PubMed ID: 33815382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic lipid A mimetic modulates human TLR4 activity.
    Piazza M; Calabrese V; Damore G; Cighetti R; Gioannini T; Weiss J; Peri F
    ChemMedChem; 2012 Feb; 7(2):213-7. PubMed ID: 22140087
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    mBio; 2017 May; 8(3):. PubMed ID: 28487429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold.
    Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A
    Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics.
    Johnson DA
    Curr Top Med Chem; 2008; 8(2):64-79. PubMed ID: 18289078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization.
    Saitoh S; Akashi S; Yamada T; Tanimura N; Kobayashi M; Konno K; Matsumoto F; Fukase K; Kusumoto S; Nagai Y; Kusumoto Y; Kosugi A; Miyake K
    Int Immunol; 2004 Jul; 16(7):961-9. PubMed ID: 15184344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic vaccines: the role of adjuvants in immune targeting.
    Jiang ZH; Koganty RR
    Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions.
    Resman N; Oblak A; Gioannini TL; Weiss JP; Jerala R
    J Immunol; 2014 Feb; 192(4):1887-95. PubMed ID: 24420921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
    Peri F; Piazza M
    Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
    Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
    Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells.
    Allam JP; Peng WM; Appel T; Wenghoefer M; Niederhagen B; Bieber T; Bergé S; Novak N
    J Allergy Clin Immunol; 2008 Feb; 121(2):368-374.e1. PubMed ID: 18036651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD14-independent responses induced by a synthetic lipid A mimetic.
    Legat A; Thomas S; Hermand P; Van Mechelen M; Goldman M; De Wit D
    Eur J Immunol; 2010 Mar; 40(3):797-802. PubMed ID: 20039305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of αGlcN(1↔1)αMan-based lipid A mimetics as a novel class of potent Toll-like receptor 4 agonists.
    Adanitsch F; Ittig S; Stöckl J; Oblak A; Haegman M; Jerala R; Beyaert R; Kosma P; Zamyatina A
    J Med Chem; 2014 Oct; 57(19):8056-71. PubMed ID: 25252784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taking toll: lipid A mimetics as adjuvants and immunomodulators.
    Persing DH; Coler RN; Lacy MJ; Johnson DA; Baldridge JR; Hershberg RM; Reed SG
    Trends Microbiol; 2002; 10(10 Suppl):S32-7. PubMed ID: 12377566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopharmacology of lipid A mimetics.
    Bowen WS; Gandhapudi SK; Kolb JP; Mitchell TC
    Adv Pharmacol; 2013; 66():81-128. PubMed ID: 23433456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antagonist activity of lipid IVa on the stimulation by lipid A of TNF-alpha production from canine blood mononuclear cells.
    Takasawa K; Kano R; Maruyama H; Hasegawa A; Kamata H
    Vet Immunol Immunopathol; 2011 Sep; 143(1-2):167-9. PubMed ID: 21782253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine.
    Gableh F; Saeidi M; Hemati S; Hamdi K; Soleimanjahi H; Gorji A; Ghaemi A
    J Biomed Sci; 2016 Jan; 23():16. PubMed ID: 26811064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.
    Dowling QM; Sivananthan SJ; Guderian JA; Moutaftsi M; Chesko JD; Fox CB; Vedvick TS; Kramer RM
    J Pharm Sci; 2014 Mar; 103(3):879-89. PubMed ID: 24464844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.